Droxidopa has 10 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Linezolid, Mao Inhibitors, Ephedrine. Patients taking Droxidopa should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 10
- Contraindicated
- 2
- Major
- 5
- Moderate
- 3
Contraindicated (2)
- Droxidopa + Linezolid— Concomitant use should be avoided due to potential for increased blood pressure.
- Droxidopa + Mao Inhibitors— Concomitant use should be avoided due to potential for increased blood pressure.
Major (5)
- Droxidopa + Ephedrine— Concomitant use may increase risk for supine hypertension due to additive blood pressure-raising effects.
- Droxidopa + Midodrine— Concomitant use may increase risk for supine hypertension due to additive blood pressure-raising effects.
- Droxidopa + Midodrine Hydrochloride— Increases risk of hypertension when used concomitantly with midodrine. Avoid concomitant use or monitor blood pressure c…
- Droxidopa + Norepinephrine— Concomitant use may increase risk for supine hypertension due to additive blood pressure-raising effects.
- Droxidopa + Triptans— Concomitant use may increase risk for supine hypertension due to additive blood pressure-raising effects.
Moderate (3)
- Droxidopa + Dopa Decarboxylase Inhibitors— May require dose adjustments for droxidopa when used concomitantly.
- Droxidopa + Rasagiline— Selective MAO-B inhibitor permitted in clinical trials but use with caution; monitor for increased blood pressure.
- Droxidopa + Selegiline— Selective MAO-B inhibitor permitted in clinical trials but use with caution; monitor for increased blood pressure.